Executive Change: Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) Appoints Rob Myers M.D. as Chief Medical Officer

Foster City, CA – Mirum Pharmaceuticals, Inc. has announced the appointment of Rob Myers as Chief Medical Officer. About Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals, Inc. is a global rare disease biopharmaceutical company focused on developing and delivering treatments for people living with severe, debilitating rare diseases, particularly rare liver conditions where the burden is profound and the unmet need is greatest. Founded in November 2018 in the San Francisco Bay Area, the company has grown into a high growth organization with team members across North America and Europe and an expanding international footprint. Mirum has built a portfolio of three approved medicines along with a broad pipeline of clinical programs targeting significant unmet needs in rare disease, underscoring its position as a leading player in this niche therapeutic area. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis, reflecting a strong focus on cholestatic and metabolic liver diseases. Mirum emphasizes urgency, sustained commitment, and close collaboration with patients and families, and has further expanded its leadership in rare disease through strategic moves such as the acquisition of Bluejay Therapeutics, strengthening its pipeline and global presence in the rare disease market.

For more information visit: https://mirumpharma.com/

Mirum Pharmaceuticals, Inc.
989 E Hillsdale Blvd Suite 300
Foster City, CA 94404
Phone: 650-667-4085
LinkedIn: https://www.linkedin.com/company/mirum-pharmaceuticals

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved